Upon its FDA approval in 2018, Teva’s migraine prevention medicine Ajovy faced tough prospects as it trailed a rival into the market with a less desirable delivery method. Nearly two years later, with an approval for an autoinjector device in hand, Teva's launch is beginning to kick into gear. 

Teva's Ajovy has been battling against intense competition in the CGRP migraine prevention field at a disadvantage: It's delivered by syringe, and its rivals use simpler, less intimidating autoinjectors. Until now. But can its own device approval drive a 25% market share grab as execs hope?

GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer.

Thursday, the FDA green-lighted two new delivery options for Nucala: an autoinjector and a prefilled syringe, both of which severe eosinophilic asthma patients can self-administer at home.